Indivumed
Indivumed is a Hamburg-based precision oncology company that combines a proprietary multi-omics database (IndivuType) of 20+ years of pre-analytically controlled tumor samples, patient-derived 2D/3D tumor models, and AI analytics to discover and validate novel cancer therapeutics for pharmaceutical, biotech, and academic partners.
- Company typePrivate
- Founded2002
- HeadquartersHamburg, Germany
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Indivumed does
Indivumed is a Hamburg, Germany-based precision oncology company that operates an integrated platform for cancer drug discovery and development, founded in 2002 and operating as Indivumed GmbH with 51–100 employees. The company's central asset is IndivuType, a proprietary multi-omics and clinical database built on 20+ years of pre-analytically controlled tumor and normal tissue samples paired with comprehensive clinical and follow-up data, covering genomics, transcriptomics, proteomics, and metabolomics. On top of this data layer, Indivumed applies AI-powered biomathematical tools — including graph analytics and a branded AI analytics platform (Onco AI-Med) — to identify novel therapeutic targets, and uses proprietary patient-derived 2D and 3D tumor models for target validation, with a stated focus on colorectal, pancreatic, lung, and breast cancers.
The commercial offering is structured as a tiered service portfolio: Target Discovery Services (multi-omics + graph analytics), Target Validation Services (patient-derived cellular models), and Therapeutic Development Services (progressing small and large molecules toward IND and beyond), supported by an expanding CRC therapeutic pipeline. Indivumed operates a B2B enterprise sales model targeting pharmaceutical and biotech companies and academic medical centers, generating revenue through R&D partnerships, co-development arrangements, and licensing rather than disclosed product pricing. Named institutional partners include the Wilmot Cancer Institute at the University of Rochester Medical Center; the company also references a global clinical network for sample acquisition and serves customers across EMEA and North America.
Capital structure is private, with a single disclosed financing event — approximately $47.7M from the European Investment Bank in January 2018 — supporting the long-horizon sample collection and platform build. The senior leadership team includes Founder Prof. Dr. Hartmut Juhl, CEO Andrew Deubler, CFO/COO Michael Gutsmann, CIO Frank Clausen, Global CMO Ronald Carter, and Chief Business Officer / Head of IndivuType Business Unit Roald Forsberg, signaling a deliberate build-out of commercial and medical leadership alongside the scientific core.
Indivumed firmographics
Firmographics- Name
- Indivumed
- Legal name
- Indivumed GmbH
- Website
- https://indivumed.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Indivumed is a Hamburg-based precision oncology company that combines a proprietary multi-omics database (IndivuType) of 20+ years of pre-analytically controlled tumor samples, patient-derived 2D/3D tumor models, and AI analytics to discover and validate novel cancer therapeutics for pharmaceutical, biotech, and academic partners.
- Ownership category
- akta.pro rank
Indivumed industry classification
Industry- Product category
- Precision Oncology Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Indivumed is headquartered
LocationHeadquarters
- HQ city
- Hamburg
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Indivumed business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Indivumed product offering
Product offeringCore offering
Indivumed operates an integrated precision oncology R&D platform for cancer drug discovery and development. It combines a proprietary multi-omics and clinical database (IndivuType) built from 20+ years of pre-analytically controlled tumor and normal tissue samples with AI-powered biomathematical tools for target discovery, patient-derived 2D and 3D tumor models for target validation, and downstream therapeutic development progressing small and large molecules toward IND. The company serves pharmaceutical, biotech, and academic partners through R&D collaborations and licensing arrangements.
Product overview
Indivumed is a precision oncology company offering an integrated platform for cancer drug discovery and development. The core offering centers on IndivuType Database, a proprietary multi-omics and clinical database with over 20 years of pre-analytically controlled tumor samples. This is complemented by Target Discovery Services using graph analytics and AI tools, Target Validation Services utilizing patient-derived 2D and 3D tumor models, and Therapeutic Development Services progressing molecules toward IND. The company also maintains a growing CRC (colorectal cancer) pipeline of novel therapeutic targets.
Differentiator
Problem solved
Functional benefit
Brands
- IndivuType: A proprietary multi-omics and clinical database containing pre-analytically controlled tumor and normal tissue samples combined with comprehensive clinical and follow-up data.
- Onco AI-Med
Products and services
- IndivuType Database A highly standardized, proprietary multi-omics and clinical database containing pre-analytically controlled tumor and normal tissue samples combined with comprehensive clinical and follow-up data, reflecting the molecular reality of cancer at an unparalleled level. Used to support target discovery and validation efforts for pharma, biotech, and academic partners.
- Target Discovery Services Discovery services based on comprehensive multi-omics and clinical data using graph analytics and AI-powered biomathematical tools to yield innovative target candidates for cancer therapeutics. Targeted at pharmaceutical and biotech partners engaged in oncology drug discovery.
- Target Validation Services In-depth target validation using cellular models derived from original patient cohorts, including proprietary patient-derived 2D and 3D tumor models for reliable target characterization. For pharma, biotech, and academic partners seeking physiologically relevant validation systems.
- Therapeutic Development Services Cancer drug discovery and development services that progress small and large molecules along the drug discovery and development pipeline toward IND and beyond. Targeted at pharmaceutical and biotech companies seeking to advance cancer therapeutic candidates.
- Patient-Derived Tumor Models Proprietary, well-characterized 2D and 3D tumor models derived from original patient cohorts that closely represent disease characteristics. Used for reliable target validation and drug profiling by pharma, biotech, and academic partners.
Quantifiable outcome
- Expanding CRC (colorectal cancer) pipeline of therapeutically novel targets demonstrates tangible results from unique approach
Companies that use Indivumed
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Indivumed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Indivumed partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Wilmot Cancer Institute at University of Rochester Medical CentercoreIndivumed and the Wilmot Cancer Institute at the University of Rochester Medical Center announced an expanded research collaboration focused on advanced stages of solid cancers such as colorectal, pancreatic, lung, and breast cancer. The partnership aims to leverage tissue and clinical data to develop patient-derived tumor models and identify new therapeutics and biomarkers using AI-powered data analytics. The collaboration may expand to other cancer types in the future.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
Indivumed competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning across multiple therapeutic areas including oncology. Directly comparable in the AI/biologic drug discovery platform category and competes for the same enterprise pharma partnership dollars.
- Exscientia: AI-driven precision medicine company that designs novel drug candidates using its platform and has active oncology programs. Competes head-to-head with Indivumed for pharma AI-discovery partnerships and shares the same end-to-end discovery-to-development thesis.
- Insitro: Machine learning-driven drug discovery company combining induced pluripotent stem cell biology, genomics, and ML. Closely comparable in combining patient-derived biology with AI for target ID and validation in oncology and other indications.
- Schrödinger: Physics-based computational platform for molecular design and predictive analytics used by pharma for hit identification and lead optimization. A direct peer in the AI/ML drug discovery tools and services space, including oncology applications.
- Caris Life Sciences: Molecular science and AI company offering multi-omics tumor profiling (DNA, RNA, protein), patient-derived models, and pharma partnership services. Closely aligned with Indivumed's combination of multi-omics + AI + patient-derived biology for oncology R&D.
- Personalis: Genomics and AI company providing tumor molecular profiling and immuno-oncology biomarker analytics, including patient-derived data assets used to support pharma oncology programs. Comparable in the multi-omics + AI oncology data space.
- Owkin: AI-precision medicine company combining federated patient data from academic centers with ML models for oncology target discovery and drug development. Directly comparable in the AI + multi-omics + academic-clinical-network model Indivumed uses.
- Champions Oncology: Provider of patient-derived xenograft (PDX) and tumor models used by pharma for oncology drug validation and biomarker discovery. Closely comparable in the patient-derived tumor model business that underpins Indivumed's target validation offering.
Broad incumbents
- Tempus AI: Large precision medicine company that combines multi-omics patient data with AI to support oncology drug development and clinical decision support. Operates at much larger scale and broader scope than Indivumed but in the same data-driven oncology discovery space.
- Foundation Medicine: Molecular profiling company providing comprehensive genomic profiling of tumors to support therapy selection and pharmaceutical R&D. Comparable in combining deep molecular tumor data with pharma/biotech commercial channels for oncology drug development.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Indivumed social profiles
Digital presenceIndivumed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Indivumed leadership team
Management profileNumber of profiles
Profiles6 records
Indivumed funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Indivumed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Indivumed
What does Indivumed do?
Indivumed operates an integrated precision oncology R&D platform for cancer drug discovery and development. It combines a proprietary multi-omics and clinical database (IndivuType) built from 20+ years of pre-analytically controlled tumor and normal tissue samples with AI-powered biomathematical tools for target discovery, patient-derived 2D and 3D tumor models for target validation, and downstream therapeutic development progressing small and large molecules toward IND. The company serves pharmaceutical, biotech, and academic partners through R&D collaborations and licensing arrangements.
Is Indivumed a public or private company?
Indivumed is a private company. It is classified as venture growth investor backed and is currently operating.
When was Indivumed founded?
Indivumed was founded in 2002. It employs 51 to 100 people.
Where is Indivumed based?
Indivumed is headquartered in Hamburg, Germany, in the Europe region.
Who are Indivumed's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Exscientia, Insitro, Schrödinger, Caris Life Sciences, Personalis, Owkin and Champions Oncology. Broad incumbents are Tempus AI and Foundation Medicine.
Does Indivumed have an API?
No public API is recorded for Indivumed.
What industry is Indivumed in?
Indivumed's product category is Precision Oncology Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.